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Abstract 
Introduction: Studies concerning vestibular schwannoma (VS) are inconsistent in 
reporting of tumor size and growth. This means that results found in one paper using 
one set of definitions cannot be compared directly with results found in another paper 
with another set of definitions. It is a challenge to make clinical decisions from studies 
with such disparate definitions, as it is difficult to know how reliable the individual 
findings are. This thesis thus aimed to empirically evaluate these different means of 
reporting tumor size and growth that can be found in the literature. In addition to this, 
we also present our own findings of the growth dynamics and predictors of untreated 
VS, as well as evaluating the treatment outcome and complication rates for tumors 
treated by gamma knife radiosurgery (GKRS).  
Methods: The management of VS patients is determined primarily based on the tumor 
size and observed tumor growth. The smallest tumors are conservatively treated by 
serial scans, and if growth is detected, they are offered active treatment by either 
microsurgery or GKRS. The papers in this thesis primarily focus on the conservatively 
treated cohort, and those among them that were later treated by GKRS. Tumor 
volumes were estimated by manual tracing on MRI. Mixed effects modeling was used 
to analyze relationships between observations. 
Results: The papers included in this thesis present a number of results.  
 The first paper found several inherent flaws with the most commonly used 
measure, the maximum diameter. Empirical proportionality coefficients which 
were quite similar to theoretical values used in the literature were also found.  
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 The second paper showed that tumor growth was best described by volume 
doubling time (VDT) rather than in terms of mm/year. We found a VDT of 4.40 
years among our cohort. We also discussed the use of a cutoff of 1 mm/year to 
distinguish between growing and non-growing tumors, and proposed a VDT 
cutoff of 5.22 years that could be used similarly. None of the baseline 
parameters investigated were predictive of tumor growth.  
 The third paper described the risk of needing treatment with the wait-and-scan 
protocol to be 13.3% at two years, and 41.3% at five years. The study also 
found a decline of hearing function for conservatively managed patients. 
Neither tinnitus nor unsteadiness changed significantly from baseline, but there 
was a reduction in the number of patients reporting vertigo. Results also suggest 
that tumor growth may be associated with progression of tinnitus and imbalance 
problems.  
 The fourth paper found a radiological tumor control rate of 71.1%. Higher age 
and larger tumor size were found to be positively associated with tumor control. 
Hearing was preserved in 79% of the patients who had serviceable hearing at 
the time of treatment. Permanent facial weakness as a result of GKRS treatment 
occurred in one patient. In terms of QoL, bodily pain and general health scores 
improved significantly after GKRS. Social function steadily declined 
throughout the follow-up period, which may be related to the increasing 
number of patients experiencing unilateral hearing loss. 
Conclusion: In the discussion of inconsistencies in reporting of tumor size and tumor 
growth, our studies propose that there exist both empirical and biological arguments 
for the use of volumes and VDT’s rather than diameters and linear growth rates. A 
VDT cutoff of 5.22 years can distinguish between clinically growing and non-growing 
tumors. Our findings support the continued use of a conservative approach among 
small, non-growing tumors. For medium-sized or growing tumors, we also suggest 
that GKRS is a preferable treatment to microsurgery, given the high tumor control 
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rates and low rates of complication with GKRS. The tumor control can also be 
improved by taking into consideration the potential predictors found in our study when 
selecting patients for this treatment, namely the patient’s age and the tumor size 
(although from a radiobiological point of view, one would expect the opposite effect 
from these parameters). Several scales of QoL were also found to improve 
significantly after GKRS, thus supporting the practice of recommending this form of 
treatment to these tumors. The social function scale however got steadily worse from 
baseline.
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Science is always wrong. It never solves a problem without 
creating ten more. 
- George Bernard Shaw 
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4. Background 
4.1 What is a vestibular schwannoma? 
4.1.1 The benign tumor 
The VS gets its name from the fact that it grows from the Schwann cells of the 
vestibular part of the vestibulocochlear nerve (CN-VIII). There still exist a number of 
misnomers in wide use, mainly due to historical reasons, such as “acoustic neuroma”, 
“acoustic neurinoma” and “acoustic neurilemmoma”, but all of these refer to the same 
condition.1;2 
As a slow-growing benign tumor, it produces symptoms related to the structures 
that it puts pressure on as it grows into the posterior fossa, occupying the 
cerebellopontine angle (CPA). The most commonly reported symptom is hearing loss,3 
with other symptoms of vertigo, balance problems and tinnitus running close behind.4 
Vertigo happens to be the symptom which is most closely associated with quality of 
life (QoL) in VS patients.5;6 In rare cases, it reaches proportions that cause it to put 
pressure onto the brainstem, thus affecting other cranial nerves – in particular the 
trigeminal nerve – or even vital functions. Classically, a presentation of unilateral 
hearing loss can lead to suspicion of VS, and taking an MRI gives the definitive 
diagnosis. Protocols for MRI vary from place to place, but the tumor is often most 
clearly delineated on T1-weighted images with gadolinium contrast.7;8 
While being by far the most frequent tumor of the CPA and also the most 
frequent among all intracranial schwannomas,9 the VS is still a rare tumor. One study 
described an incidence of 570 occult tumors per 100,000 temporal bones, but this 
number is likely an overestimate considering that the temporal bones were investigated 
because of suspected pathology in the first place.10 On the other hand, based on the 
number of VS diagnosed each year in the United States, one gets a value for the 
incidence of about 1 per 100,000 per year. As Rosenberg states, this suggests that the 
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vast majority do not become clinically evident, and that the realistic incidence is 
probably in between these two numbers.10 Furthermore, the incidence is continually 
growing – likely due to improved imaging standards – now estimated at approximately 
13/million/year.11;12 The incidence rates have also been related to a number of 
sociodemographic factors such as level of education and marital status.13 
VS also appear in another condition called neurofibromatosis type 2 (NF-2), an 
inherited disease caused by mutations of the Merlin gene, where multiple 
schwannomas grow symmetrically on CN-VIII.14 Patients with bilateral tumors such 
as this are often excluded from VS studies because the growth patterns of NF-2 tumors 
are more aggressive than those of unilateral VS, and they are more difficult to treat.15-
18 
 
4.1.2 Historical review 
VS was probably first described in 1777 in an autopsy report by Sandifort, but 
the first successful treatment did not come before 1894, by Sir Charles Ballance.10 
Early mortality rates were high, up to 75% in some reports. Harvey Cushing was able 
to reduce this mortality rate to 11% towards the end of his career.10 Several others also 
developed strategies to further reduce the mortality rate, and today, mortality rates 
with surgical resection are very low.19  
Surgery was the first choice for treatment of VS for a long time, but with the 
advent of gamma knife radiosurgery (GKRS) in 1967,20 an increasing number of 
patients opt for this treatment instead. The treatment is described in further detail in a 
later section of this paper. 
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The introduction of MRI has allowed for the detection of increasingly smaller 
tumors, as evidenced by the diameter of diagnosed tumors dropping from 35 mm in 
1979 to 10 mm in 2006 in one study.21 At this stage, many are asymptomatic and are 
not likely to grow, further increasing the need for conservative treatment of diagnosed 
tumors. 
 
4.2 Treatment 
4.2.1 Decision management for treatment 
There exist a wide range of management options for the treatment of VS. Many 
centers including ours choose to conservatively manage the smallest tumors, offer 
active treatment by either GKRS or microsurgery to medium- to large-sized tumors, 
and propose microsurgery for the largest tumors. Other factors such as age, co-
morbidity and patient preferences also play a role.22 Some centers are more restrictive 
with the use of conservative management and prefer early active treatment,23 while 
others are more preferential towards microsurgical treatment24. 
 
4.2.2 Treatment options 
4.2.2.1 Conservative management 
Most VS are slow-growing. As a result, keeping in mind the risks behind any 
active treatment procedure, a protocol of watchful waiting is often implemented 
initially. This particularly applies to patients with small tumors, or elderly patients. 
With this conservative treatment, the patient is invited to come back for serial MRI 
scans after a predetermined time period; usually, the next images are taken after one, 
two and five years, although some may be observed more closely if deemed necessary. 
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If growth is detected on these scans when compared to previous scans, active treatment 
is offered, in the form of either microsurgery or GKRS.22 
Conservative management became a viable alternative to microsurgery because 
imaging technology allowed for the detection of VS at smaller sizes, often at an 
asymptomatic stage as described above. The reason it stands as a good option for 
slow-growing tumors is that side-effects of treatment, in particular surgery, may 
deteriorate QoL more than the tumor itself.25-27 However, recent studies propose that 
there may be advantages in active treatment by GKRS at an earlier time point for 
improved hearing preservation.23 One study demonstrated an economic advantage with 
conservative management rather than microsurgical treatment or GKRS, given the 
assumption that delaying treatment would cause more complications.28 
 
4.2.2.2 Microsurgery 
Microsurgery is a surgical procedure that aims to remove the tumor physically, 
either by total or subtotal resection. With the exception of symptoms produced by 
brainstem and cerebellar compression in very large tumors (i.e. hemiparesis, headache 
and ataxia),29;29 symptom relief is generally not an expected outcome of this or any 
other treatment procedure – although this is disputed by some.30-32 Symptoms are not 
expected to improve because the damage done to the cranial nerves of the internal 
acoustic meatus tends to be irreversible. 
Three main methods exist for this surgical technique, known as the 
translabyrinthine, suboccipital retrosigmoid and middle fossa approaches.33 While the 
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translabyrinthine approach does not involve any brain retraction, it does destroy 
hearing, whereas the two other approaches allow for some hearing preservation.33-36 
Besides the risk of hearing loss, there are other risks involved with these 
surgical procedures, most commonly damage to the facial nerve and the trigeminal 
nerve.19;37-39 These risks are reportedly higher than with radiosurgery.37;40-43 Other 
complications such as infections, cerebrospinal fluid fistulas and hydrocephalus also 
occur.25;44;45 
The length of hospitalization is furthermore well over a week including the 
convalescence period, and patients lose on average 60 workdays after microsurgical 
treatment of VS.46 
 
4.2.2.3 Gamma knife radiosurgery 
4.2.2.3.1 Introduction 
Invented by the Swedish neurosurgeon Lars Leksell in 1967, GKRS is the other 
active treatment alternative. Unlike microsurgery, this treatment does not aim to 
remove the tumor, but rather to arrest its growth, leaving the tumor bulk in place.47;48 
However, bear in mind that few studies find a direct relationship between tumor 
growth and clinical symptoms,49-54 suggesting that symptom progression may be 
multifactorial. One study even found that tinnitus was a more common symptom if the 
tumor was small.55 Nonetheless, it is evident that continued growth, if left alone, will 
eventually result in pressure on nearby structures and hence also symptom 
development. 
GKRS is also known by the term “stereotactic radiosurgery”, which perhaps 
describes the process of it better, as the procedure uses stereotactic delivery of 
radiation from 60Co sources. That is, doses of radiation are delivered from many 
21 
 
 
 
 
different angles, with an additive effect where these beams meet. The three-
dimensional irradiation field is planned beforehand so as to have a high cumulative 
dose delivered to the site of the tumor itself while avoiding sensitive structures nearby, 
such as the trigeminal and facial nerves.56 This is particularly important considering 
that this is a single-dose treatment, without fractionation. The procedure at our center 
is described in more detail in section 7.5. 
Historically, high tumor control rates were achieved with margin doses (i.e. the 
low dose delivered to the periphery of the tumor) of around 20 Gy, but the 
complication rates were unacceptably high as well (see section 4.2.2.3.6 for more 
detail about these complications). As a result, the margin dose was reduced to 12-13 
Gy, where similar tumor control rates were found, but complication rates were 
lowered.57;58 In particular, studies have shown that the cochlear dose is related to 
hearing outcome.59-63 
GKRS is also frequently used to treat a wide range of other intracranial tumors, 
from primary tumors such as meningiomas and gliomas64-66 to metastases from other 
tumors66;67. 
 
4.2.2.3.2 Definition of tumor control 
Tumor control rather than symptom relief is the primary aim of GKRS. 
However, the literature on GKRS contains a number of definitions for the term “tumor 
control”. While some studies consider the need for retreatment as the marker of 
treatment failure, others use imaging-based definitions – for example that tumors 
growing >2 mm/year after treatment with GKRS are considered treatment failures.  
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Chopra et al. argue that tumors increasing slightly in size after GKRS either 
stabilize or regress afterwards, and that freedom from surgical resection is an endpoint 
that avoids classifying these as failures.68 However, since this transient swelling often 
subsides after six months,69 a sufficiently long follow-up period can also circumvent 
the issue. Furthermore, imaging-based definitions allow for a more objective 
classification, since the reasons for retreatment may vary between centers.70 An 
advantage of using retreatment-free survival rather than imaging-based definitions is 
that it can account for other clinical considerations as well. 
“Progression-free survival” is a term that combines both of these, thus 
describing the number of patients after a given time period that have not been retreated 
or have had a tumor that has not grown (although the definition for growth, as 
described in section 4.3.2, may still vary). 
 
4.2.2.3.3. Transient swelling after GKRS 
As described above, while the aim of GKRS treatment is to lead to growth 
arrest, many of these studies find that there is an initial increase in tumor volume 
shortly after treatment. The swelling, also described by the term 
“pseudoprogression”,71 is caused by build-up of edema rather than representing 
increased tumor bulk. This expansion tends to subside after less than a year,69 and is 
observed to occur in up to 74% of cases.72;73 
Despite being a transient phenomenon, this swelling is not necessarily 
unproblematic: in larger tumors it can lead to increased headache, dizziness and facial 
pain caused by compression to the brainstem. This may necessitate decompressive 
surgery in a few cases. 
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4.2.2.3.4 Loss of contrast enhancement 
Besides change in tumor size, another common term found in the literature to 
describe efficacy of GKRS treatment is loss of contrast enhancement.69;70;74-77 This is 
supposed to indicate central necrosis induced by the GKRS treatment. However, 
studies by Scheller et al. point out the fallacy of using such a measure without a 
standardized protocol with defined timing of image acquisition, namely that contrast 
enhancement varies with time.78;79 
 
4.2.2.3.5 Selected literature review 
Selected studies on the GKRS for VS are presented below, sorted into separate 
tables based on their definition of tumor control. The definitions are not always 
entirely uniform from one study to another, however. Both prospective and 
retrospective studies were chosen. The size of the studies ranged from as few as 30 
patients to 829 patients in one case. High rates of tumor control were found with the 
individual definitions, although those studies based on retreatment-free survival were 
clearly higher, as could be expected. Rates of hearing preservation varied quite a bit, 
ranging from 50-82%.  
It must be pointed out that these studies are too disparate in their study 
populations to be directly comparable. Some include patients with NF-2 for example, 
while others exclude them. Others include patients with tumors that have been treated 
previously, and yet others have selected tumors above a certain size, or patients of a 
particular age range. The result is that it would be impossible to conduct a meta-
analysis of the articles presented here.  
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More detailed systematic reviews on this subject have been written by Weil et 
al80 and Bassim et al18, to name some examples.
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4.2.2.3.6 Complications 
Hearing loss after GKRS occurs in up to 50% of cases, as shown in Tables 1 
and 2. In theory, such a hearing loss could be caused by the treatment or by the tumor 
itself. These are usually difficult to distinguish, but Régis et al. designed a randomized 
study where they demonstrated that GKRS might have a protective effect on hearing 
levels.23  
Other complications associated with radiosurgical treatment are facial or 
trigeminal nerve deficits, tinnitus, vertigo, and imbalance.22;55;92-94 Some patients also 
get shunt-requiring hydrocephalus after treatment.45;95 The majority of these 
complications occur months to years after treatment.92;96 Acute complications such as 
neurological deficits, seizures or death are uncommon.92 Rarely, more serious 
complications such as radiation necrosis of the brain,97 malignant brain edema98 or 
malignancy99;100 are also reported. 
 
4.2.2.3.7 Predictors 
It would be clinically useful to have the means to predict whether GKRS 
treatment for a given patient would lead to tumor control or not. Some investigators do 
not find any usable predictors.101 Other studies find that smaller tumors are easier to 
treat by GKRS.86;102;103 This can be explained from a radiobiological point of view, in 
terms of higher oxygenation levels being found in small-sized tumors.104 Genetic 
factors have also been implicated in the susceptibility for tumor control.105 
Equally interesting is the prospect of predicting when complications of the 
treatment would occur. However, studies can tend to show contradictory results.55 
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Several studies have demonstrated that the cochlear dose is related to hearing 
outcome.59-63 Small tumor volume, young patient age, high-level hearing before 
treatment and intracanalicular tumor location have also been positively associated with 
the rate of hearing preservation.63;86;106  
 
4.2.2.3.8 Quality of life 
 Our group found lower SF-36 scores after GKRS treatment than in the 
Norwegian population,37 similarly to what was found in a German cohort107. A Dutch 
study found no such association, i.e. that GKRS did not have much impact on general 
QoL compared to normative data.108 
Comparisons with the general population, however, do not necessarily give 
much information with regard to which form of treatment is most preferable. To 
function as an argument in this sense, it is necessary to compare the various treatments 
with each other in terms of QoL. Our study found that the difference from normative 
scores was significantly greater in the microsurgery group than in the GKRS group in 
a few of the scales (physical functioning, role-physical and role-emotional).37 Régis et 
al similarly find that microsurgically treated patients have lower QoL than patients 
treated by GKRS.109 Other groups on the other hand found little difference between 
treatment groups.110 A review by Whitmore et al found better QoL results for GKRS 
compared to both microsurgery and conservative management.94 
Other parameters can also be considered. The same review as above related 
complications of type of treatment to QoL, finding that the complications from 
microsurgery and wait-and-scan strategies had a greater negative effect on patient lives 
than the complications from radiosurgery.94 Also, delayed radiosurgery was found to 
have a superior impact on QoL as compared to primary radiosurgery.26 
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4.2.2.4 Fractionated radiotherapy 
The term “fractionated radiotherapy” refers to when the radiation is delivered to 
the target volume in 2-5 sessions, instead of in a single dose.56 Several centers use 
fractionated radiotherapy for VS treatment, with tumor control rates ranging above 
91% and low complication rates.47;111;112  
The motivation for choosing fractionation in malignant tumors is that it reduces 
the risk of injury to normal tissue, a conclusion stemming from radiobiological studies 
of cell culture lines of malignant cells.56 Generalized to VS, this could conceivably 
lead to improved hearing preservation, for example.83 However, Niranjan et. al argue 
that the rationale may not be transferable to slow-growing, benign tumors such as the 
VS, since such tumors are difficult to study in cell culture or animal models. As a 
result, they may well have a different radiobiology with respect to fractionation.56 
 
4.3 Growth 
4.3.1 Measurement 
Many algorithms for the management of VS focus largely on either the size of 
the tumor, or its growth over a period of time. As a result, the method of measuring the 
tumor’s size is of importance. Even though the most important requirement for a 
measurement method is its reliability, there are other factors that play in as well. Time 
is a highly limiting factor, for example; in the busy everyday clinical practice, the 
process of measurement should ideally be as little time-consuming as possible. As a 
result, a slightly inaccurate measurement that takes a few seconds to perform will 
easily be preferred over a highly accurate measurement that takes several minutes. The 
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aim is thus to find an approximation method that is easy to do, but still yields 
sufficiently reliable values. Few methodological studies have focused specifically on 
VS,113-117 but volumetric studies of other tumors have suggested that irregular shapes 
such as that of VS50 are poorly managed by approximation methods118;119. 
Both size and growth are evaluated by a number of different measurement 
methods that are widely used in the literature. For example, size can be measured as a 
single diameter in millimeters,120 corresponding to growth being described in terms of 
millimeters per year. Alternatively, volumes can be assessed, either by the 
measurement of diameters in multiple dimensions, or by area tracing of individual 
slices.121;122 This allows for growth to be described as volume doubling times (VDT). 
More complex formulas for the assessment of size are also used by some.10;120;123 
Manual, semi-automatic and fully automated methods of measurement exist.124 
 
4.3.2 Definition 
What should be counted as growth? A semantic definition merely focusing on 
one number being larger than another ignores two important arguments: one, that one 
must account for measurement errors, and two, that not all increases in volume are 
clinically relevant. To exemplify the latter point, a tumor with a tiny growth over a 
long period of time is not as worrying as a tumor with large growth over a short period 
of time, and in turn may not require treatment. Indeed, it is the growth rate that often 
stands as a criterion for treatment; a fast-growing tumor is conceivably at high risk for 
evolution of symptoms, and should be treated before it gets that far. 
In the literature, a value of >1 mm/year is often taken as clinically relevant 
growth.125 The arbitrary nature of this value is important to recognize, but nevertheless 
it is useful to have a reference value for clinical practice. 
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4.3.3 Predictors of growth 
Assuming that growth leads to worsening symptoms, knowledge of predictors 
of tumor growth would allow for more targeted treatment strategies: one could treat 
the tumors that would come to grow while avoiding actively treating tumors that 
would not grow. However, many studies that have investigated potential predictors of 
growth have been unable to identify any.9;10;126-128 These studies have considered a 
wide range of possible predictors, from age to sex to initial symptoms to initial tumor 
size, to mention a few.  
Other studies are more promising in their results. Presence of symptoms,129-131 
extrameatal tumor localization,130 larger tumor size,123;129;131-133 left-sided tumors134 
and younger patients123;134 have all been associated with either tumor growth or failure 
of conservative management. Several studies suggest that previously detected growth 
can predict continued growth.125;135-138  
 
4.4 Natural history 
4.4.1 Definition 
The “natural history” of a tumor such as this refers to the progress over time of 
these tumors in terms of some parameter. Most commonly, with regard to tumors, this 
is the growth rate and/or growth proportion, but could also be complications, 
development of symptoms, etc.  
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4.4.2 Search terms 
To make a literature review of the natural history of untreated VS, a careful 
selection of search terms was needed. The search was restricted to articles published in 
the English language within the last ten years. 
For articles about the vestibular schwannoma, the MeSH term “Acoustic 
Neuroma” was used, and the “[Majr]” suffix appended since the term should be a 
major topic of the articles in question. One major advantage of using a MeSH term is 
that it is unnecessary to include other synonyms in this search. For the natural history, 
several terms could be used, separated by an “OR” command. This included a set of 
synonyms including “natural history”, “growth rate”, “volume change”, etc. Likewise 
could be done for the conservative treatment, where synonyms included “conservative 
treatment”, “untreated”, “wait-and-scan”, etc.  
Additionally, it was preferred not to include papers that focus primarily on NF-
2 patients, who often get bilateral VS, and whose tumors are known to have a different 
growth pattern than unilateral VS.15 Since “Neurofibromatosis 2” is a subheading of 
the MeSH term “Acoustic Neuroma”, the NF-2-related papers were attempted 
removed by adding the “[NoExp]” suffix to the above “Acoustic Neuroma” search 
term. An additional search was performed where all papers with the MeSH term 
“Neurofibromatosis 2” were excluded, in case this strategy gave different results. 
The full search parameter used to conduct this search can be found in the 
appendix. 
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4.4.3 Parameters 
The primary parameter was the growth rate itself. However, as noted earlier, 
“growth rate” is not a uniformly defined parameter. As a result, the results were 
organized according to the growth model that was used. 
The proportion that grew or shrank was also defined, as well as the proportion 
that required intervention. 
The following parameters were considered to evaluate the strength of the study: 
year of publication, number of subjects included, months of follow-up, percentage 
lost-to-follow-up, and study design (primarily in terms of whether the study was 
prospective or retrospective). 
 
4.4.4 Search results 
A total of 31 articles were found in the first search, but at first glance it was 
clear that several papers on NF-2 had been included. The second search found 24 
articles, and better managed to remove the NF-2-related articles.  
Three of these 24 articles were excluded because of duplicates; since some of 
the studies appeared to be reviewing the same data material after different intervals, 
only the most recent of these was included. One article was excluded because it was 
not an original article, but rather a letter to editor. Four of the articles were excluded 
because of study populations that did not match our criteria (details in appendix). Two 
articles were excluded because they did not examine any of the relevant parameters. 
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Two of the articles were pure literature reviews and had not investigated growth 
dynamics themselves. These articles will be discussed in a later section of this paper. 
The excluded articles are listed in the appendix. The remaining 12 articles were 
included in this systematic review. 
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4.4.5 Growth dynamics 
There are several kinetic models that can be used to describe growth, ranging 
from using units of mm/year to evaluating the VDT. All the articles that had 
investigated this parameter, except for one, had reported growth in terms of mm/year, 
which also reflects the fact that this is the most commonly used.  
The mean growth rate reported in studies ranged from 0.7-4.0 mm/year. Some 
studies only mentioned the growth rate among a subgroup of their tumors, namely the 
tumors that were growing, rather than among the full set. These studies are explicitly 
marked in Table 3. As can be expected, these studies were also the ones that found the 
highest growth rates. Barring these, the highest mean growth rate found was 1.24 
mm/year. It is understandable that many researchers preferred to exclude the non-
growing tumors from the growth rate analysis, as the large proportion of unchanged 
tumors (up to 64%) and shrinking tumors (up to 22%) can easily skew these values. It 
is however an interesting discussion to find out which of these strategies is the most 
appropriate for reporting growth rates. 
Intervention was given for different reasons in the different studies, ranging 
from growing tumors to increasing symptoms. As is intuitive, the largest percentage 
that required intervention was found in the study that had the longest mean follow-up 
time. 
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4.4.6 Study strength 
The year of publication is a relevant parameter of study strength because it 
reflects the current knowledge and technology at that time. In particular it can be 
pointed out that some of the earlier studies included varying proportions of patients 
followed up by use of CT scans rather than MRI scans. For one thing, most 
intracanalicular tumors are very difficult to detect on CT scans. T1-weighted MRI 
scans with gadolinium contrast give the most accurate imaging of these tumors,7 and 
as a result, MRI has in recent times replaced CT completely. From this one can infer 
that the studies that include patients followed by CT are less reliable than those that 
strictly used MRI. 
There was a large variation in both the number of subjects (from 21 to 386) 
and the follow-up time (from 25.5 to 121 months). With the heterogeneous behavior 
of this tumor, as shown by the number in the different growth categories, it would be 
an advantage to have a large number of participants to follow. Likewise with the 
follow-up time; keeping in mind the slow growth of these tumors and errors involved 
in measurements, longer follow-up times are necessary to be able to make reasonable 
conclusions about the material. 
Two of the studies136;140 had relatively high rates of loss to follow-up, greater 
than 10%. Notably, there were many studies (five of the 12 studies included) that did 
not define how many of the participants were lost during the follow-up period.  
Study design was assessed by reviewing the inclusion criteria where possible, 
otherwise the authors’ own description was used. There seemed to be an 
approximately equal number of prospective and retrospective studies in this 
collection. It can be mentioned that prospective studies tend to be more reliable than 
retrospective studies, in part due to the risk of selection bias in retrospective studies. 
That is, since patients with growing tumors tend to get treatment when this is 
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detected, the cohorts of patients in retrospective studies are more likely to include 
high proportions of non-growers. 
Just as with the studies about GKRS treatment (Tables 1 and 2), the inclusion 
criteria of these studies were too variable to compare them directly. To name the 
same example as above: most of the studies excluded NF-2 patients, while others 
included these patients alongside those with sporadic VS. 
 
4.4.7 Existing systematic reviews 
Among the articles found above, there were a total of four systematic reviews 
on the subject registered in PubMed, published within the last ten years. There was 
one more systematic review which did not appear in the search results, but was found 
via the “Related articles” function provided in PubMed. It was presumably not found 
because it does not explicitly mention in the text that the patients were conservatively 
treated. Furthermore, one more systematic review from 2000 was also included here 
in this list, despite being beyond the ten-year scope of this overview. One of the 
articles described above also included a review of some articles, and is therefore also 
included on this list. Finally, one review was excluded because it did not include any 
of the relevant study parameters. 
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The reviews are summarized below in Table 5. 
Authors, year No. of studies 
included 
Range of 
publication 
years 
Range of 
subjects 
Range of 
follow-up 
(months) 
Range of 
growth rate 
(mm/yr) 
Range of 
observed 
growth(%) 
Martin et al, 
2009139 
11 2000-2008 72-729 25.5-121 - 22-53 
(calculated) 
Battaglia et al, 
2006142 
6 1997-2006 - 29-80 - 13-32 
Yoshimoto et al, 
2005145 
26 1991-2002 12-127 6-64 0.4-2.4 15-85 
(calculated) 
Yamakami et al, 
200340 
13 1994-2001 24-123 2.0-4.4 0.35-3.22 29-82 
Shin et al, 
200393 
4 1998-2000 46-162 12-120 - 4.3-25 
Rosenberg et al, 
200010 
17 1985-1999 3-571 13-56 0.6-2.9 14.3-75 
Table 5 – Systematic reviews of the natural history of the vestibular schwannoma, published since 2000 
       
As we see here, studies show a wide range of results in both growth rates and 
observed growth. In our own review of the literature, the highest growth rates were 
found among those that focused explicitly on growing tumors. While it was not 
investigated in detail for these systematic reviews, it is likely that many of the higher 
numbers (growth rate of up to 3.22 mm/year in one study, and observed growth of up 
to 85%) might stem from similar subset analyses. 
It must be pointed out that there is a great deal of overlap not only between 
these studies but also with our literature review, in that a number of the articles could 
be found in several of the reviews. 
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5. Aims of present study 
5.1 Overall aim 
Studies concerning VS are inconsistent in reporting of tumor size and growth. 
This means that results found in one paper using one set of definitions cannot be 
compared directly with results found in another paper with another set of definitions. 
It is a challenge to make clinical decisions from studies with such disparate 
definitions, as it is difficult to know how reliable the individual findings are.  
This thesis thus aimed to empirically evaluate these different means of 
reporting tumor size and growth that can be found in the literature. In addition to this, 
we also present our own findings of the growth dynamics and predictors of untreated 
VS, as well as evaluating the treatment outcome and complication rates for tumors 
treated by GKRS.  
 
5.2 Paper I117 
This paper compared different methods of measuring the size of VS. These 
were evaluated in terms of agreement with measurements conducted by the slice area 
method, a highly accurate measurement method which is based on manual tracing of 
the tumor on all visible images. Measurement consistency with repeated 
measurements was also evaluated for each method, as well as being validated by 
measurements performed by a neurosurgeon and a neuroradiologist. 
 
5.3 Paper II 
This paper described the growth dynamics of untreated VS, and also attempted 
to find out whether there were factors available at presentation which could predict 
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later growth. Different growth models that are used in the literature were also 
evaluated. 
 
5.4 Paper III146 
This paper evaluated the effect of an initial conservative management in terms 
of efficacy, QoL and severity of audio-vestibular symptoms.  
 
5.5 Paper IV 
This paper evaluated the degree of tumor control which was achieved by 
GKRS treatment of growing tumors. Predictors of tumor control and QoL were also 
investigated. 
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6. Summary of papers 
6.1 Paper I117 
In this volumetric study of the vestibular schwannoma, we evaluated the 
accuracy reliability of several approximation methods that are in use. We also found 
empirical proportionality coefficients for the different methods. Measurements were 
done using multiple modalities on 252 images of vestibular schwannoma. The most 
commonly used approximation method, the maximum diameter, was found to have 
inherent weaknesses that need to be considered. 
 
6.2 Paper II 
In this prospective study we aimed to describe growth dynamics within a 
cohort of 178 consecutive patients with conservatively managed VS. We also 
compared different growth models (mm/year, cm3/year, VDT), and investigated the 
capability of baseline parameters to predict future growth. Based on the actual 
measurements, we found that the VDT was the most correct way to describe VS 
growth. We found that a cutoff value of 5.22 years provided the best value in order to 
distinguish growing tumors from non-growing tumors. None of the baseline 
predictors that we investigated were usable as predictors of growth. 
 
6.3 Paper III146 
A total of 193 patients with conservatively treated sporadic unilateral VS were 
enrolled into a prospective study aiming to evaluate the effect of an initial 
conservative management in terms of efficacy, QoL and severity of audio-vestibular 
symptoms. We found a small but statistically significant improvement in vestibular 
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complaints, and no change in the occurrence of tinnitus. With the exception of 
hearing loss caused by surgery, treatment did not affect symptoms or QOL 
significantly. Growth was associated with the occurrence of tinnitus and balance 
problems. 
 
6.4 Paper IV 
This prospective study evaluates the outcome after GKRS in terms of tumor 
control and complication rates, in a series of 45 patients treated by GKRS because of 
growing tumors. Post-treatment growth rates are compared to pre-treatment growth 
rates, and predictors of tumor control were investigated. We found high tumor control 
rates and low rates of complications. Several of the SF-36 (Short Form General 
Health Survey) scales were significantly affected. 
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7. Methods 
7.1 Treatment algorithm 
It was initially attempted to randomize a cohort of patients with tumors with a 
maximum diameter ≤25 mm at diagnosis, into treatment groups of microsurgery or 
GKRS. However, this study design was changed because of patients’ reluctance to 
undergo randomization.41;42;147 The algorithm used since divides patients with VS into 
categories based on CPA tumor size and observed tumor growth. Patients with 
tumors <20 mm in diameter are conservatively managed, which means that they are 
followed up at 1, 2 and 5 years with reimaging and clinical evaluation. If growth is 
observed, the patients are offered active treatment by microsurgery or GKRS. If the 
tumor is initially found to be between 20 and 25 mm, active treatment is offered. 
Tumors greater than 25 mm are treated by microsurgery.22 
 
7.2 Imaging 
Diagnosis and radiological follow-up at our center was conducted by MRI, 
with the exception of a few patients who instead had to be followed up by CT 
scanning for medical reasons (these few patients were excluded from all of the papers 
in this thesis). Ideally, a thin-slice (2-3 mm) T1-weighted pulse sequence with 
gadolinium contrast was used, since with this setup, the tumor can easily be 
delineated on the image series. However, complete standardization of the imaging 
protocol was not achieved, partly because many patients had their follow-up imaging 
performed at a center close to their residence, where the images were subsequently 
sent to us. 
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Measurements were performed as described in section 4.3.1 using the imaging 
software AGFA Impax (AGFA, Mortsel, Belgium) on a Fujitsu Siemens workstation 
with NEC MDview 212 high-resolution screens. 
7.3 Clinical variables 
A number of clinical variables were recorded at each consultation. Information 
about balance problems (yes/no), tinnitus (yes/no and VAS) and vertigo (yes/no and 
VAS) were prospectively recorded in a case report form and entered into a database. 
The VAS (visual analog scale) is a scoring tool for assessing patients’ complaints, 
where they are asked to mark their degree of complaints from zero (no complaints) to 
100 (worst possible).  
Hearing preservation was evaluated by the help of the Gardner-Robertson 
scale, which is based on pure tone audiogram and speech discrimination scores, and 
graded from A (good/excellent hearing) to D (no hearing).148 Facial nerve function 
was graded according to the House-Brackmann scale, from 1 (normal facial nerve 
function) to 6 (total paralysis).149 
 
7.4 Quality of life 
QoL was assessed by way of SF-36, which consists of a survey that is given to 
patients. It includes eight scales derived from the patients’ responses: bodily pain, 
physical function, role physical, general health, vitality, social function, role 
emotional and mental function. These are scored from 0 to 100, where lower scores 
indicate more severe symptoms.150 
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7.5 Gamma knife radiosurgery 
On the day of their treatment, the patients undergo a pre-radiosurgery 
evaluation with audiological tests and facial nerve assessment. They also get a cranial 
MRI taken once they have had an MRI-compatible Leksell stereotactical frame fixed 
to their head, with the purpose of keeping the head immobilized. This MRI is taken 
using a T1-weighted pulse sequence with gadolinium contrast, with 1.1 mm slices. A 
T2-weighted CISS series with contrast is often also taken, when hearing preservation 
is a priority.  
   
© Jobin K. Varughese, 2011 
The dosimetry is then planned with the aim of achieving a prescription dose of 
12 Gy to the periphery of the tumor. This margin dose is constructed in such a way as 
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to cover >95% of the tumor while avoiding healthy cranial nerves and other sensitive 
structures, thus minimizing the risk of complications. This conformal planning is 
achieved by using multiple beams through individual collimators as described above. 
 
 
© Jobin K. Varughese, 2011 
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Both the B and 4C models (after 2008) have been used for the dose delivery 
itself. The head is repositioned for each beam, and the energy is delivered as planned. 
 
7.6 Statistics 
7.6.1 Mixed effects modeling 
Mixed effects models include both fixed and random effects. Fixed effects 
describe overall relationships with covariates, while random effects are random 
differences between clusters at different levels.151;152 One particular advantage of 
mixed effects models is that it is a generalization of linear regression that allows 
taking clustering into account, where clustering in this case is when there are multiple 
observations for each patient.117 
 
7.6.2 Kaplan-Meier survival 
Kaplan-Meier survival analysis allows for description of survival within a 
single group, or to compare different groups. This type of analysis can also be used to 
account for censoring, which is when an observation is only known to exceed a 
certain value153 – for example when a patient has been lost to follow-up after a 
number of years, in which case one cannot know for sure of this patient’s survival 
statistics. 
 
7.6.3 Bland-Altman plots 
For graphical depiction of the relationships between the values obtained by the 
different measurement modalities in our first paper, we used Bland-Altman 
plots.154;155 When data are logarithmically transformed, these are plots of the 
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geometric means of the measurements against their ratio on a logarithmic scale. With 
these plots, the closer one gets to horizontal reference intervals, a narrow reference 
interval, and ratios approximately equal to one, the more reliable one can say that the 
measurement modality in question is.117 
 
7.6.4 Logistic regression 
The purpose of logistic regression is to predict the probability of an event, 
when the outcome variable can be answered as yes/no.153 From such an analysis, one 
can find the odds ratios of the event taking place, based on different values of each 
explanatory variable adjusted for the other explanatory variables. 
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8. Discussion 
8.1 Studies’ strengths and weaknesses 
Our center receives a large proportion of the VS patients in Norway. Assuming 
a similar distribution of intracranial schwannomas as reported in the literature, 156 we 
can claim that 466 of the 518 intracranial schwannomas registered in Norway in the 
period 2000-2006 (data from Norwegian Cancer Registry) were VS. We included 355 
patients in the same period, suggesting that we receive over 75% of the VS patients in 
Norway.12 A comprehensive prospective database has been collected as these patients 
have been followed up. 
This presents several advantages. To take an example, we minimize the risk of 
selection bias that exists in retrospective studies. We were also able to use a study 
design that evaluated outcome after GKRS treatment and compared it to pre-
treatment growth rates, which, to our knowledge, no other studies have done.157 It is 
also an advantage in itself to be able to describe the growth dynamics of VS at a near-
population level. However, it must be mentioned that these studies have quite short 
follow-up periods; particularly studies on late outcomes after GKRS treatment require 
longer follow-up to make conclusive statements.18 As mentioned earlier in the text, 
we were also unable to standardize the MRI imaging, which stands as a weakness of 
these studies.  
 
8.2 Results 
The papers included in this thesis present several conclusions. The first paper 
found three inherent flaws with the most commonly used measure, the maximum 
diameter (MD): it was the least accurate method in terms of agreement with the 
reference method, had the largest intraobserver variation, and was the only 
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approximation method which systematically underestimated the volume of small 
tumors and overestimated the large ones. This last finding means that a formula is 
required to find the corresponding volume for a given diameter, rather than to 
multiply a simple proportionality coefficient as with the other approximation 
methods. Empirical proportionality coefficients which were quite similar to 
theoretical values used in the literature were also found.24;114 
The second paper showed that tumor growth data fit best with a VDT-based 
growth model, rather than in terms of mm/year which is more common in the 
literature. We found a VDT of 4.40 years among our cohort. We also discussed the 
use of a cutoff of 1 mm/year to distinguish between growing and non-growing tumors 
in the literature,128 and proposed a VDT cutoff of 5.22 years that could be used 
similarly. None of the baseline parameters investigated were predictive of tumor 
growth. 
The third paper described the risk of needing treatment with the wait-and-scan 
protocol to be 13.3% at two years, and 41.3% at five years. The study also found a 
decline of hearing function for conservatively managed patients (compared to 59.8% 
at baseline, 39.8% had retained hearing at three years, and 42.4% at end of follow-
up). Neither tinnitus nor unsteadiness changed significantly from baseline, but there 
was a reduction in the number of patients reporting vertigo. QoL was largely 
unchanged throughout the follow-up, and was not affected by treatment either. 
Vertigo was found to significantly reduce QoL. Results also suggest that tumor 
growth may be associated with progression of tinnitus and imbalance problems. To 
our knowledge, this is the most detailed study of symptom development and QoL in 
conservatively managed VS. 
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The fourth paper found a radiological tumor control rate of 71.1% and a five-
year retreatment-free survival rate of 93.9%. This low tumor control rate might be 
because of the inclusion of growing tumors only, the short follow-up period, or that 
the definition we used for tumor control was too conservative. Higher age and larger 
tumor size were found to be positively associated with tumor control. Most studies 
find the opposite conclusion.86;102;103 Furthermore, from a radiobiological point of 
view, one would expect better results for the younger patients and smaller tumors 
because of the higher oxygenation levels in these tumors.104 Hearing was preserved in 
79% of the patients who had serviceable hearing at the time of treatment. Permanent 
facial weakness as a result of GKRS treatment occurred in one patient. In terms of 
QoL, bodily pain and general health scores improved significantly after GKRS. 
Social function steadily declined throughout the follow-up period, which may be 
related to the increasing number of patients experiencing unilateral hearing loss.
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9. Conclusion 
In the discussion of inconsistencies in reporting of tumor size and tumor 
growth, our studies propose that there exist both empirical and biological arguments 
for the use of volumes and VDT’s rather than diameters and linear growth rates. A 
VDT cutoff of 5.22 years can distinguish between clinically growing and non-
growing tumors. 
Our findings support the continued use of a conservative approach among 
small, non-growing tumors. The reasoning for this is multifaceted. A patient should 
not be exposed to unnecessary treatment if the tumor would never have grown 
enough to elicit symptoms anyway. Furthermore, there is limited evidence that early 
treatment is beneficial. For medium-sized or growing tumors, we also suggest that 
GKRS is a preferable treatment to microsurgery, given the high tumor control rates 
and low rates of complication with GKRS. The tumor control can also be improved 
by taking into consideration the potential predictors found in our study when 
selecting patients for this treatment, namely the patient’s age and the tumor size. This 
finding is surprising, as one would expect the opposite effect from these parameters. 
Several scales of QoL were also found to improve significantly after GKRS, thus 
supporting the practice of recommending this form of treatment to these tumors. The 
social function scale however got steadily worse from baseline. 
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10. Errata 
Paper I, II, IV 
No corrections. 
 
Paper III 
 Slice volumes were estimated by multiplying the sums of slice areas by 
the slice interval, not the slice thickness. 
 The “House-Brackmann” scale is incorrectly referred to as the “House-
Brachman” scale instead. 
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